关于使用克拉迪布林片作为多发性硬化症稳定老年患者的退出疗法的叙述性审查
Jerome de Seze1, Dominique Dive2, Xavier Ayrignac3
1Department of Neurology, Strasbourg University Hospital, Strasbourg, France. jerome.deseze@chru-strasbourg.fr.
Neurology and therapy
|April 8, 2024
概括
患有复发性多发性硬化症 (RMS) 的老年人可能会从克拉迪宾片 (CladT) 作为退出治疗中受益. 在CladTT上装饰.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 老年病的医生 老年病的医生
背景情况:
- 诊断为复发性多发性硬化症 (RMS) 的老年人患病率越来越高.
- 在老年RMS患者中,传统疾病修饰疗法 (DMT) 的疗效降低.
- 在老年多发性硬化患者中,对并发症,感染和不良事件的敏感性更高.
研究的目的:
- 审查克拉迪宾片 (CladT) 在老年RMS患者中的治疗特性.
- 评估CladT作为"退出疗法"的潜力,以停止持续的DMT给药.
- 评估CladT在老年多发性硬化症患者中的疗效和安全性.
主要方法:
- 从涉及RMS群体的随机试验中对后期分析的审查.
- 对长期随访数据的检查.
- 对老年人使用克拉德里宾片的现实世界证据的分析.
主要成果:
- 尽管需要进一步的老年人数据,但CladT的疗效似乎与年龄无关.
- 没有观察到与年龄相关的显著不良安全信号,包括淋巴缺血症.
- 对于CladT来减轻与老年人持续免疫抑制治疗相关的风险的潜力.
结论:
- 克拉迪布林片可以作为一个有价值的"退出疗法"老龄化RMS患者.
- 对于具有并发症和多药的老年患者,考虑CladT是有必要的.
- 建议包括更新疫苗,以最大限度地降低老年患者的感染风险.
相关概念视频
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176
Drug Administration and Therapy Phases: Overview
454
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
454
Psychosis: Goals of Pharmacotherapy
124
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
124


